EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making

Mary Summer Starling iD, Lindsay Kehoe iD, Bruce K Burnett, Phil Green, Karthik Venkatakrishnan iD, Rajanikanth Madabushi

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3467 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Mary Summer Starling und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Clinical Trials Transformation Initiative, Duke Clinical Research Institute, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Disease Progression, Drug Development, Decision Making. Die Arbeit nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While some model‐informed drug development frameworks are well recognized as enabling clinical trials, the value of disease progression modeling (DPM) in impacting medical product development has yet to be fully realized. The Clinical Trials Transformation Initiative assembled a diverse project team from across the patient, academic, regulatory, and industry sectors of practice to advance the use of DPM for decision making in clinical trials and medical product development. This team conducted a scoping review to explore current applications of DPM and convened a multi‐stakeholder expert meeting to discuss its value in medical product development. In this article, we present the scoping review and expert meeting output and propose key questions that medical product developers and regulators may use to inform clinical development strategy, appreciate the therapeutic context and endpoint selection, and optimize trial design with disease progression models. By expanding awareness of the unique value of DPM, this article does not aim to be technical in nature but rather aims to highlight the potential of DPM to improve the quality and efficiency of medical product development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ProgressionDrug DevelopmentDecision MakingHumansClinical Trials as Topic

Autor:innen und Institutionen

  • The Clinical Trials Transformation Initiative, Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
  • Division of Allergy, Immunology and Transplantation, National Institutes of Health, Bethesda, Maryland, USA.
  • Patient Advocate, Winchester, California, USA.
  • EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts, USA.
  • Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Mary Summer Starling, Lindsay Kehoe, Karthik Venkatakrishnan

Zitieren

APA

Starling, M. S., Kehoe, L., Burnett, B. K., Green, P., Venkatakrishnan, K., & Madabushi, R. (2025). The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3467

Vancouver

Starling MS, Kehoe L, Burnett BK, Green P, Venkatakrishnan K, Madabushi R. The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3467

BibTeX
@article{Starling2025,
  author = {Starling, Mary Summer and Kehoe, Lindsay and Burnett, Bruce K and Green, Phil and Venkatakrishnan, Karthik and Madabushi, Rajanikanth},
  title = {The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3467}
}
Kostenlos starten →